Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Internal Medicine • Hematology
What is your approach to CMV prophylaxis in the post-allogeneic stem cell transplant setting?
Are you routinely using letermovir as CMV prophylaxis in high-risk patients?
Any special considerations with its use versus other antiviral agents?
What is your approach to duration of prophylaxis with any of the above agents?
Answer from: Medical Oncologist at Academic Institution
We do not routinely use letermovir but we are looking carefully at this data.
We use prophylactic ganciclovir pre transplant and high dose acyclovir post transplant in high risk patients and are reviewing this data as well.
Sign in or Register to read more